UNSPSC 51322705: Pravastatin sodium

This classification denotes an antilipemic fungal metabolite, anticholesteremic agent, and hydroxymethylglutaryl-coa reductase inhibitor with the molecular formula C23H35O7.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3M8608UQ61, chemically known as 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1s-(1alpha(betas*,deltas*),2alpha,6alpha,8beta(r*),8aalpha))-1-naphthaleneheptanoic acid but more generally known as pravastatin sodium, which bears US NIH Compound Identifier 54687.

UNSPSC 51322705 Pravastatin sodium is a Commodity code covering pharmaceutical supply contracts by state and local health agencies, fire and rescue departments, and cooperative purchasing alliances. State and local governments buy this and related cardiovascular medications primarily through emergency medical services procurement, pharmacy benefit programs, and multistate cooperative purchasing agreements. The work involves supplying finished pharmaceutical products meeting FDA requirements, cGMP standards, and Drug Supply Chain Security Act compliance, with vendors managing product specifications by National Drug Code, expiration-date maintenance, cold-chain logistics where required, and Safety Data Sheet documentation under OSHA standards. Issuing bodies include city purchasing departments (Tampa Fire Rescue), state health agencies (Texas HHS), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states).

Recent activity spans the Gulf Coast and Upper Midwest. The City of Tampa's Purchasing Department posted an Invitation for Bid (IFB) in April 2026 for Advanced Life Support Medications (Solicitation 26P00188, due April 8, 2026) requesting cardiovascular and emergency-response medications for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year initial term plus renewal options; the solicitation included a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission issued a Request for Information in April 2026 exploring direct-to-manufacturer prescription distribution models outside traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Department of Administration's MMCAP, serving multiple states including Oregon, issued a Request for Proposal (RFP) in January 2026 (due March 26, 2026) to establish multistate contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with pricing weighted 75 percent in the evaluation and contract effectiveness set for July 1, 2026. The code shows active solicitation by municipal fire and rescue, state Medicaid and pharmacy benefit programs, and cooperative purchasing vehicles.